Take­da’s gene edit­ing part­ner is snapped up for $250M cash as sec­tor con­tin­ues to heat up

Look­ing to make genome edit­ing its “fourth pil­lar” of op­er­a­tions, Japan’s AnGes is buy­ing out Take­da-part­nered Emen­do­Bio for $250 mil­lion — and with it, tech­nol­o­gy de­signed to push past the cur­rent lim­i­ta­tions of CRISPR gene edit­ing.

AnGes led Emen­do­Bio’s $61 mil­lion Se­ries B a lit­tle less than a year ago, con­tribut­ing $50 mil­lion and up­ping its stake in the New York biotech to 32%. Now it’s snap­ping up the rest, mak­ing Emen­do an in­de­pen­dent but whol­ly-owned sub­sidiary.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.